Yemaachi Biotech · Jul 2026
Describes Yemaachi’s AACR 2026 presence, including a CEO-chaired session on multi-omic technologies and the role of TACA in expanding African representation in cancer research.
Diversifying precision cancer diagnostics and treatments
Company research
Public company, workplace, funding, and market signals
Overview
Ghana-based biotech company focused on precision oncology in African populations, building the Yemaachi Cancer Knowledge Base / African Cancer Atlas and offering diagnostic and sequencing services.
Primary product
The African Cancer Atlas (TACA) / Yemaachi Cancer Knowledge Base
Founded
2020
Headquarters
1 Round House Road, Abelempke, Accra, Ghana
Team size
11-50 employees
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
Precision oncology / cancer genomics
Offices
Abelempke, Accra, Ghana
Nairobi, Kenya
Washington, DC, United States
Business model
B2B research collaborations
diagnostic and sequencing services
grant-funded research programs
consortium / platform access for pharma and academic partners
Funding
Stage
seed
Total raised
$29.4M
Latest round
Grant · Mar 2024
Latest amount
$25M
People & investors
Leadership
Co-Founder & CEO
Co-Founder & CTO
Co-Founder / Head of Technical Services
Co-Founder & CFO / CBO
Director, Operations & Regulatory Affairs
Vice President, Strategic Partnerships
Director of Clinical Affairs
Director - Commercial Projects / Country Director - Kenya
Head of Genetics
Representative, Francophone Africa / Molecular Epidemiology
Abdoulaye Diallo
Bioinformatics & Machine Learning
Work & culture
Mission-driven and people-first, with official values emphasizing respect, empowerment, excellence, inclusivity, trust, and putting people ahead of profit.
Work style
Onsite
Benefits
internships
mentorship
hands-on experience
cross-functional exposure across finance, bioinformatics, molecular biology, software engineering, and marketing
Product & market
Pricing
Not publicly disclosed; services appear to be a mix of partner-led research, grants, and paid sequencing/diagnostic services.
Differentiators
- —Focus on African genetic diversity and underrepresented populations
- —Pan-African clinico-genomic cancer datasets
- —On-continent sequencing and data generation
- —African Clinical Cancer Research Network (AfriCAN)
- —Partnership with Roche on The African Cancer Atlas
- —Combination of research, diagnostics, and sequencing services
- —Free access to TACA data for African-based researchers
Technology
immunogenomics
bioinformatics
machine learning
artificial intelligence
next-generation sequencing
whole-genome sequencing
whole-exome sequencing
targeted sequencing
whole RNA sequencing
long-read sequencing
clinical database / knowledge base
diagnostic laboratory workflows
Customers
African hospitals and clinical partners
African academic and research institutions
pharmaceutical partners
researchers working with de-identified data
patients enrolled in clinical studies across Africa
Competitors
Color
Verily
23andMe
Everlywell
Molecular You
IndyGeneUS AI
Genomelink
OmeCare
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
3.5K
Traffic estimate as of Jun 2026
Latest news
Yemaachi Biotech · May 2026
Reports early TACA implementation across five countries, 236 recruited participants, and operational challenges such as IRB timelines, biospecimen transport, and FFPE quality.
GenomeWeb · Apr 2026
External coverage of AACR-related work and TACA, including recruitment across multiple countries and the broader precision-medicine significance of African ancestry genomics.
Forbes Africa · Feb 2026
Profiles Yaw Bediako and the company’s progress, including the African Cancer Atlas, scale-up plans, and the company’s next fundraising ambitions.
Yemaachi Biotech · Feb 2025
Launches TACA with Roche as founding/anchor partner; aims to generate genomic and clinical data from up to 7,500 African cancer patients (15,000 genomes) and make the database free for African-based researchers.
Jobs and careers at Yemaachi Biotechnology
0 jobs at Yemaachi Biotechnology
No open positions
Check back later for new openings